ADC Therapeutics SA（ADCT）于8月13日公布了第二季度财务数据。数据显示，公司当季运营亏损为2541.4万美元，而此前IBES（Institutional Brokers' Estimate System，机构经纪商预估系统）的市场预期仅为2440万美元，实际亏损幅度超出预期。与此同时，该公司第二季度净亏损为1656.5万美元，相较之下，市场普遍预估的净亏损额为3400万美元，实际亏损水平显著低于预期。这一结果反映出公司在运营成本控制与财务表现上存在一定的不确定性。
ADC Therapeutics SA（ADCT）于8月13日公布了第二季度财务数据。数据显示，公司当季运营亏损为2541.4万美元，而此前IBES（Institutional Brokers' Estimate System，机构经纪商预估系统）的市场预期仅为2440万美元，实际亏损幅度超出预期。与此同时，该公司第二季度净亏损为1656.5万美元，相较之下，市场普遍预估的净亏损额为3400万美元，实际亏损水平显著低于预期。这一结果反映出公司在运营成本控制与财务表现上存在一定的不确定性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.